SSU72 homolog, RNA polymerase II CTD phosphataseGenealiases: HSPC182 · PNAS-120
Q-omics provides the consensus-scored SSU72 profile across patient tissues and cancer cell-line models. SSU72 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SSU72 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SSU72 protein abundance shows 21,088 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where SSU72 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSU72 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSU72 survival associations across molecular data types. SSU72 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSU72 RNA expression–survival associations across cancer types. High SSU72 expression shows unfavorable associations in KICH, ACC, LGG, UCEC, LIHC and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SSU72 RNA expression.
This table summarizes SSU72 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SSU72. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSU72 shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in LIHC, STAD and BLCA. The KIRC box plot shows higher SSU72 RNA expression in normal versus tumor tissue (log2 FC = −0.523, t-test p < 0.001).
This table shows molecular features associated with SSU72 in patient tissues and cancer cell lines. In patient samples, SSU72 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SSU72 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
